Variations In The Immune System Explain Differences In Severity In Muscular Dystrophy

Genetic polymorphism of gene CD40 of the immune system is responsible for differences in severity of the Duchenne muscular dystrophy.

Better understanding of Duchenne muscular dystrophy (DMD), one of the most common lethal genetic disorders has been stated in a new paper, co-written by faculty at Binghamton University, State University of New York, increases the.

This could pave way for potential therapeutic approaches.

Muscular Dystrophy / Duchenne Muscular Dystrophy - Overview
Overview about muscular dystrophy, a muscle disease characterized by muscle weakness and muscle wasting.

‘The role of immune system in DMD will help is the discovery of of new therapeutic agents that target the changes.’

DMD, the most common of many types of muscular dystrophy, generally occurs in young boys, where they first show signs of muscle weakness in early school years. The disease then gradually destroys muscle tissue, so that boys lose the ability to walk in their early-mid teens, and then later succumb to respiratory or cardiac failure.

All patients with DMD have gene mutations in the dystrophin gene so that they do not make dystrophin protein in muscle tissue. The dystrophin gene is the largest gene in the human genome. A lack of dystrophin protein was discovered as the cause of DMD by Hoffman in 1987.

While all DMD patients share the same genetic and protein problem in muscle, they often show differences in the severity of their disease. Some are particularly severe (losing ambulation at just 8 or 9 years of age), whereas others are much less severe (walking until their 20s).

BioMarin DMD Drug Data Not Persuasive Enough: FDA
The evidence supporting BioMarin's application for drisapersen is weak and that the drug doesn't appear to be effective in Duchenne muscular dystrophy (DMD).

"The findings suggest that the immune system has an important role in the muscle disease of Duchenne muscular dystrophy," said Eric Hoffman, professor of pharmaceutical sciences and associate dean for research at Binghamton University's School of Pharmacy and Pharmaceutical Sciences.

Hoffman and his colleagues sought to determine why different DMD patients responded differently to the same loss of the dystrophin protein in their muscle.

Duchenne Muscular Dystrophy Drug (Ataluren) Will be Available on NHS
Ataluren(Translarna) to be made available in National Health Services for treatment of Duchenne Muscular Dystrophy in children below the age of 5.

After studying hundreds of DMD patients, they confirmed that the gene CD40, an important modulator of the immune system, held a polymorphism that modified the severity of Duchenne muscular dystrophy. Polymorphisms are subtle differences in genes that dictate the color of hair, height, skin color and many other aspects that make each person unique.

"Slight differences in the immune system lead to different reactions regarding the muscular dystrophy. The immune system needs to be balanced: too much or too little is a bad thing in any immune response. This balance may be shifted in muscular dystrophy due to the CD40 polymorphism," said Hoffman.

DART Lab's Duchenne Muscular Dystrophy Awareness Week
Duchenne Awareness Day 2016 focuses on early diagnosis which goes a long way in beginning early treatment and physiotherapy programs.

"If a genetic polymorphism of CD40 leads to milder disease in DMD, then it follows that drugs targeting CD40 may also improve patient symptoms," added Hoffman. "This research opens new therapeutic avenues to try to develop therapies for DMD."

The paper, Association Study of Exon Variants in the NF-kB and TGFb Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy was published in The American Journal of Human Genetics.

Source-Medindia